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Available online 16 December 2008Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an expanded
CAG repeat in the HD gene that results in cortical and striatal degeneration, and mutant
huntingtin aggregation. Current treatments are unsatisfactory. R6 transgenic mice replicate
many features of the human condition, show early onset of symptoms and fast disease
progression, being one of the most used models for therapy screening. Here we review the
therapies that have been tested in these mice: environmental enrichment, inhibition of
histone deacetylation and methylation, inhibition of misfolding and oligomerization,
transglutaminase inhibition, rescue of metabolic impairment, amelioration of the diabetic
phenotype, use of antioxidants, inhibition of excitotoxicity, caspase inhibition,
transplantation, genetic manipulations, and restoration of neurogenesis. Although many of
these treatments were beneficial in R6 mice, they may not be as effective in HD patients, and
thus the search for a combinationof therapies thatwill rescue thehumanconditioncontinues.
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To address the question of CAG repeat stability in the mouse
genome, Mangiarini et al. (1996) created transgenic mice with
truncated fragments of the mutant huntingtin gene, referred
to as the R6 lines. The authors were surprised to find that
these fragments were sufficient to generate a neurological
phenotype that was similar to Huntington's disease (HD) in
humans (Mangiarini et al., 1996). Among the five original lines,
the R6/1 and R6/2 have been the most studied. These mice
express exon 1 of the human HD gene (which corresponds to
3% of the entire gene) with approximately 115 (R6/1) and 150
(R6/2) CAG repeats (Mangiarini et al., 1996). Thesemice, and in
particular the R6/2 line, have an early onset of symptoms and
a fast progression of the disease, showing a life expectancy of
approximately 12 to 17 weeks, depending on the colony.
The phenotype and neuropathology observed in thesemice
replicate several features observed in humans, including a
progressive motor (Carter et al., 1999; Luesse et al., 2001;
Bolivar et al., 2003, 2004) and cognitive impairment (Lione et
al., 1999; Murphy et al., 2000), weight loss, decreased striatal
and brain size (Mangiarini et al., 1996), ubiquitinated nuclear
and cytoplasmic inclusions of the mutant protein (Davies et
al., 1997; Li et al., 1999), altered levels of neurotransmitters (for
review see Cha, 2000) and their receptors (Cha et al., 1998),
altered gene expression (Luthi-Carter et al., 2000, 2002, 2003;
Zucker et al., 2005), diabetes (Hurlbert et al., 1999; Luesse et al.,
2001; Andreassen et al., 2002; Björkqvist et al., 2005), which
was previously reported in 10–25% of HD patients (Podolsky et
al., 1972; Farrer, 1985), as well as several other neuroendocrine
changes (Björkqvist et al., 2006; for review see Petersén and
Björkqvist, 2006), and premature death (Mangiarini et al.,
1996). Interestingly, both R6/2 (Gil et al., 2004, 2005) and R6/1
(Lazic et al., 2004, 2006) mice show a specific decrease in
hippocampal cell proliferation and neurogenesis, which may
account for some of their cognitive deficits (see below).
However, despite showing gross brain and striatal atrophy
(Mangiarini et al., 1996), R6/2 mice show minimal neuronal
loss in the striatum. To date, only one study reported a 25%
decrease in the total number of striatal cells in 12-week-old
transgenic mice (Stack et al., 2005), while another described a
marked increase in the number of apoptotic cells in the
striatum (Keene et al., 2002) of 13 week-old R6/2 mice. On theother hand, “dark cell degeneration” has also been described
in a small number of neurons in 12- (Stack et al., 2005) and 14-
week-old mice (i.e., at a very late stage in the development of
the disease) (Iannicola et al., 2000; Turmaine et al., 2000; Yu et
al., 2003). Moreover, a progressive loss of orexin neurons was
found in the lateral hypothalamus of R6/2 mice, which was
correlated with the occurrence of narcoleptic-like episodes
(Petersén et al., 2005) and seemed to be related with a
disintegration of the sleep–wake cycle and of the circadian
rhythm in these mice (Morton et al., 2005b). Furthermore, a
loss of retinal ganglion neurons was reported in these
transgenic animals (Helmlinger et al., 2002).2. Therapeutic strategies
Although clinically relevant, it is particularly challenging to
perform therapeutic trials in HD patients for several reasons:
(1) The low prevalence of the disease oftenmakes it difficult to
recruit a sufficient number of patients; (2) Due to the slow
progression over many years, drugs that are hypothesized to
affect disease progression may require very long follow up
periods; (3) There is substantial variability in the rate of
progression, even in patients with similar CAG repeats
(Squitieri et al., 2002); (4) There are no well-established
biomarkers (i.e., quantifiable measures that change predicta-
bly with disease progression) for HD, whichmeans that for the
most part, clinical trials have to rely on subjective clinical
rating scales as outcome parameters; (5) There are no
established methods to assess disease progression in pre-
clinical gene carriers; (6) Therapies in mutation carriers early
in the disease will probably have minor benefits and may
cause adverse effects. Once a reliable set of biomarkers for HD
progression becomes available, it will be possible to test the
efficacy of many therapies in preclinical gene carriers in
delaying disease onset. These biomarkers will allow the
design of clinical trials with shorter durations and smaller
groups of patients (Wild and Tabrizi, 2006). Thus, it is
particularly important that all novel therapies for HD are
extensively tested in cell cultures and animal models before
studied in patients.
In this perspective, the R6 transgenic lines have served as a
useful tool to evaluate new therapeutic strategies and are
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purpose. However, the accelerated phenotype in R6 mice
may not reflect the actual human condition and, in some
circumstances, reduce the ability to detect subtle improve-
ments due to a specific therapy. Moreover, the number of CAG
repeats that are expressed in these mice (approximately 115
and 150 repeats in the R6/1 and R6/2 lines respectively) do not
reflect the number of repeats (approximately 39) that cause
themost common adult-onset form of the disease in humans.
In fact, in humans longer repeats are normally associatedwith
high allele instability during paternal transmission and result
in juvenile and infantile cases that are characterized by amore
severe phenotype and a faster progression of the disease (for
review, see Gil and Rego, 2008). Thus, it is reasonable to
suggest that the R6 transgenic lines reflect more accurately
the infantile/juvenile HD cases than the adult-onset form of
the disease.
It is also important to note that therapies that are predicted
to function at the level of the full-length mutant huntingtin
are unlikely to be optimal to test in this model, which
expresses a truncated form of the mutant protein. Further-
more, both genetic (e.g., number of CAG repeats) and
environmental factors (e.g., number of pups in a litter,
maternal nutrition status, age at weaning, cage size, degree
of environmental enrichment, diet, number of animals per
cage, etc.) can contribute to the overall wellbeing and survival
of the mice, and consequently to the observed results (Hockly
et al., 2003b). Thus, these factors should be taken into
consideration when comparing the effects of different ther-
apeutic strategies. Moreover, the search for therapies is also
dependent on a careful standardization of experimental
protocols (namely on the use of appropriate behavioral tests)
and a sophisticated statistical approach to analyze the
outcome parameters. In this respect, a careful study by Hockly
et al. (2003b) has shown that rotarod performance, grip
strength and weight loss produce quantitative, reliable and
reproducible data that can be easily analyzed by standard
statistical methods and reveal the progressive nature of the
disease. In a subsequent study (Hickey et al., 2005), R6/2 mice
were shown to present behavioral deficits in tests of motor
function, namely the running wheel activity and climbing
behavior, as early as 4.5 weeks of age, a time when rotarod
performance and grip strength were still normal. Power
calculations further showed that the running wheel test was
appropriate for efficient drug screening at this early stage
(Hickey et al., 2005). On the other hand, one should keep in
mind that the specific cause for the progressive behavioral
deterioration of R6 mice, such as the decrease in rotarod
performance, is not completely understood. Indeed, the
peripheral features of the R6 pathology may also contribute
for the progressive decline in the ability to perform certain
behavioral tests including the rotarod. Finally, although it has
been observed that R6 mice can die with epileptic seizures
(Mangiarini et al., 1996; Gil et al., unpublished observations),
the actual cause of death of these mice is still unknown and
deserves further investigation.
So far, most of the experimental treatments that have
been tested in R6 mice, have focused on drug administration.
However, alternative therapeutic strategies, including genetic
manipulations and transplantation, have also been studied(Table 1). Many of these treatment paradigms have been
found to exert ameliorative effects on the behavior and
neuropathology of these transgenic mice and to increase
their survival by up to 40%. However, one should be careful
when interpreting these results, since the actual beneficial
effects of these various treatments in this and other animal
models can only be properly inferred after performing
controlled clinical trials in human HD patients. Nevertheless,
the R6 mice have constituted an invaluable tool to screen
potential therapies for the treatment of this devastating
disorder. In the following sections we will review the
therapeutic strategies (along with some molecular mechan-
isms related to HD pathogenesis) that have been evaluated to
date in these transgenic mouse lines.
2.1. Environmental enrichment
Environmental enrichment can be beneficial in different
experimental models of neurodegeneration (Johansson, 1996;
Young et al., 1999). Two independent groups have analyzed
the effect of an increased environmental stimulation on the
phenotype and neuropathology of R6 mice (Carter et al., 2000;
van Dellen et al., 2000; Hockly et al., 2002; Glass et al., 2004;
Spires et al., 2004). These studies have demonstrated that the
exposure of R6/1 (van Dellen et al., 2000; Glass et al., 2004;
Spires et al., 2004) or R6/2 (Hockly et al., 2002) mice to an
enriched environment (consisting of large standard cageswith
cardboard, paper and plastic objects, which were changed
every two to three times per week) delayed the onset of motor
symptoms, decreased the severity of the clasping phenotype,
and reduced the loss of the peristriatal cerebral volume. Carter
et al. (2000) also demonstrated that, improving the access to
food and water had beneficial effects.
Although it is not clear how enrichment exerts its
beneficial effects on disease progression, the structural
changes in the brain, such as plasticity and neurogenesis
that result from exposure to a stimulating environment
(Kempermann et al., 1997; Gould et al., 1999; van Praag et al.,
1999), could improve neuronal function and stimulate
protective mechanisms in the brain, retarding the degenera-
tive process. As stated above (Section 1), both R6/1 (Lazic et
al., 2004, 2006) and R6/2 mice (Gil et al., 2004, 2005) show
reduced hippocampal neurogenesis. Therefore, it is possible
that the beneficial effects observed in an enriched environ-
ment may be due, at least in part, to a restoration of the
neurogenic process. In agreement with this hypothesis,
25 week-old symptomatic R6/1 mice housed in an enriched
environment (from 4 weeks of age), were shown to have an
increase number of proliferating cells [bromodeoxyuridine
(BrdU)-positive] and migrating neuroblasts (doublecortin-
positive) in the dentate gyrus (DG) of the hippocampus as
compared to control R6/1 mice housed in standard condi-
tions (Lazic et al., 2006), showing that an enriched environ-
ment can indeed restore hippocampal neurogenesis in these
transgenic mice.
On the other hand, it has been shown that an enriched
environment can have beneficial effects at the level of gene
transcription or protein transport, which in turn can con-
tribute to an improvement in synaptic function and plasticity
(for review, Hannan, 2004). In agreement with this hypothesis,
Table 1 – Therapeutic strategies for HD tested in R6 transgenic mice grouped according with their mode of action
Treatment Mouse
line
Effect on RR
performance
Effect on
survival
Reference Clinical trials
Environmental enrichment
Environmental enrichment R6/1 n.d. n.d. van Dellen et al., 2000
Glass et al., 2004
Spires et al., 2004
Lazic et al., 2006
Environmental enrichment R6/2 ↑ performance
(accelerated RR)
n.d. Hockly et al., 2002
Environmental enrichment and
enhanced diet
R6/2 n.d. ↓ early
deaths
Carter et al., 2000
Inhibition of histone deacetylation and methylation
SAHA R6/2 ↑ performance
(accelerated RR)
n.d. Hockly et al., 2003a,b
Sodium butirate R6/2 ↑ performance ↑ 20.8% Ferrante et al., 2003
Chromomycin R6/2 n.d. ↑ 13.1% Stack et al., 2007b
Mithramycin R6/2 ↑ performance ↑ 29.1% Ferrante et al., 2004
Mitramycin + cystamine R6/2 ↑ performance ↑ 40% Ryu et al., 2006
Inhibition of misfolding and oligomerization
Overexpression of Hsp70 R6/2 n.d. no effect Hansson et al., 2003
Overexpression of Hsp27 R6/2 n.d. no effect Zourlidou et al., 2007
Congo red R6/2 ↑ performance ↑ 14.2% Sánchez et al., 2003
no effect no effect Wood et al., 2007
Trehalose R6/2 ↑ performance ↑ 10.1% Tanaka et al., 2004
C2-8 R6/2 ↑ performance no effect Chopra et al., 2007
Tiagabine R6/2 ↑ performance
(10 and 12 weeks)
↑ 17.5% Masuda et al., 2008
Transglutaminase (Tgase) inhibition
“Tissue” Tgase ablation R6/1 ↑ performance ↑ 12% Mastroberardino
et al., 2002
Cystamine R6/2 n.d. ↑ 10.7% Karpuj et al., 2002
↑ performance ↑ 19.5% Dedeoglu et al., 2002
n.d. n.d. Wang et al., 2005a,b,c
Energy supplementation and rescue of metabolic impairment
A2a agonist: CGS21680 R6/2 ↑ performance no effect Chou et al., 2005
A2a antagonist: SCH 58261 R6/2 no effect n.d. Domenici et al., 2007
Creatine R6/2 ↑ performance ↑ 17.4% Ferrante et al., 2000
↑ performance ↑14.4% Dedeoglu et al., 2003
Dichloroacetate R6/2 ↑ performance ↑ 5.8% Andreassen et al.,
2001b
Pyrimidine nucleoside: PN401 R6/2 ↑ performance ↑ 10% Saydoff et al., 2006
Pyrimidine nucleoside: KP544 R6/2 ↑ performance n.d. Dey et al., 2007
Antioxidants
Essential fatty acids R6/1 n.d. n.d. Clifford et al., 2002
Lipoic acid R6/2 n.d. ↑ 7.1% Andreassen et al.,
2001a
Ascorbate R6/2 n.d. n.d. Rebec et al., 2003
n.d. n.d. Rebec et al., 2006
Co-enzyme Q10 R6/2 ↑ performance ↑ 25.3% Smith et al., 2006 No effect (Feigin et al.,
1996; Huntington Study
Group, 2001)
TUDCA R6/2 ↑ performance n.d. Keene et al., 2002
BN82451 R6/2 ↑ performance
(10 weeks)
↑ 15.3% Klivenyi et al., 2003
Clioquinol R6/2 ↑ performance ↑ 20% Nguyen et al., 2005
Inhibition of excitotoxicity
Remacemide + Co-enzyme Q10 R6/2 ↑ performance ↑ 31.8% Ferrante et al., 2002 No effect (Huntington
Study Group, 2001)
Riluzole R6/2 no effect
(accelerated RR)
↑ 10.2% Schiefer et al., 2002 ↓ chorea (Huntington
Study Group, 2003)
(continued on next page)
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Table 1 (continued)
Treatment Mouse
line
Effect on RR
performance
Effect on
survival
Reference Clinical trials
no effect n.d. Hockly et al., 2006 No effect (Landwehrmeyer
et al., 2007)
mGluR2 agonist: LY379268 R6/2 no effect ↑ 9.5% Schiefer et al., 2004
mGluR5 antagonist: MPEP ↑ performance ↑ 13.5%
Ceftriaxone R6/2 n.d. n.d. Miller et al., 2008
Deafferentation of: corticostriatal
pathway nigrostriatal pathway
R6/2 n.d. ↑ 13.4% Stack et al., 2007a
n.d. ↑ 21.3%
Caspase inhibition
Caspase-1 dominant negative R6/2 ↑ performance ↑ 20% Ona et al., 1999
Caspase inhibitor: zVAD-fmk ↑ performance ↑ 25%
Inhibitors of Caspases 1 and 3
(YVAD-fmk+DEVD-fmk)
R6/2 ↑ performance ↑ 17.3% Chen et al., 2000
Overexpression of Bcl-2 R6/2 no significant effect ↑ 10.3% Zhang et al., 2003
Minocycline R6/2 ↑ performance ↑ 14% Chen et al., 2000 ↑ neuropsychological
and motor function
(Bonelli et al., 2004)
n.d. n.d. Wang et al., 2003
no effect n.d. Smith et al., 2003
Minocycline+Co-enzyme Q10 R6/2 ↑ performance ↑ 18.2% Stack et al., 2006
Alternative pharmacological therapeutic strategies
Lithium R6/2 ↑ performance
(heavier mice)
no effect Wood and Morton,
2003
Anti-inflammatory drugs:
acetylsalicylate and rofecoxib
R6/2 no effect no effect Norflus et al., 2004
Anti-convulsants: gabapentin or
gabapentin-lactam
R6/2 n.d. no effect
↑14% n.s.
Zucker et al., 2004
Combination: acetylcholinesterase
inhibitor (tacrine) and
antidepressant
(moclobemide)+creatine
R6/2 no effect minor effect Morton et al., 2005a
Sedative: chloral hydrate R6/2 n.d. ↓ survival Pallier et al., 2007
Benzodiazepine: alprazolam ↑ performance no effect
Transplantation
Striatal transplantation R6/2 n.d. n.d. Dunnett et al., 1998
Anterior cingulate cortical
transplantation
R6/1 n.d. n.d. van Dellen et al., 2001
Transplantation of C17.2 stem
cells into the lateral
ventricles + trehalose
R6/2 n.d. Up to ↑
26.3%
Yang and Yu, 2009
Genetic manipulations
Anti-huntingtin siRNA R6/2 ↑ performance ↑ 12.4% Wang et al., 2005a,b,c
Anti-huntingtin shRNA R6/2 n.d. n.d. Huang et al., 2007
Lentiviral GDNF R6/2 n.d. n.d. Popovic et al., 2005
Therapies aimed to restore neurogenesis
asialoEPO R6/2 no effect n.d. Gil et al., 2004
FGF2 R6/2 ↑ performance ↑ 20% Jin et al., 2005
Adenoviral (BDNF+Noggin) R6/2 ↑ performance ↑ 16.8% Cho et al., 2007
Voluntary exercise R6/2 n.d. n.d. Kohl et al., 2007
Antidepressant: fluoxetine R6/2 n.d. n.d. Grote et al., 2005
Antidepressant: sertraline R6/2 ↑ performance
(10 weeks)
↑ 20% Peng et al., 2008
Note. n.d., not determined; RR, rotarod.
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1 mice maintained in an enriched environment is correlated
with a delayed loss of cannabinoid CB1 receptors (Glass et al.,
2004), and that an enriched environment entirely rescues the
severe decrease of cortical DARPP-32 (dopamine and cyclic-
adenosine monophosphate regulated phosphoprotein of amolecular weight of 32 kDa) and striatal brain-derived
neurotrophic factor (BDNF) (in this case by possibly promoting
the anterograde transport of this neurotrophin from the
anterior cortex to the striatum) that are observed in
5 month-old R6/1 mice (Spires et al., 2004). Furthermore, in
this last study, the enriched environment was also shown to
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mice (Spires et al., 2004). Since BDNF has been shown to
increase neurogenesis (Benraiss et al., 2001; Pencea et al.,
2001), an appealing hypothesis is that the restoration of
hippocampal BDNF levels by enriched environment may
lead to an increase hippocampal neurogenesis, which can in
turn contribute to the observed behavioral improvements.
Based on these studies, many groups are now using an
enriched environment as the standard housing for these
mice, and any given therapy would need to exert additional
effects to be proven effective (Hockly et al., 2003b). The
described findings also suggest that promoting environmen-
tal stimulation could have an effect on disease progression
by improving the quality of life of patients afflicted with this
disorder.
2.2. Inhibition of histone deacetylation and methylation
Post-translational modifications of histones (e.g. acetylation,
methylation, phosphorylation) contribute to the overall
chromatin structure and play an important role in the
regulation of gene transcription. Transcriptional dysregula-
tion might play a role in the pathogenesis of HD, and several
transcription abnormalities have been reported in the R6/2
mouse model (for review see Cha, 2000). Furthermore, data
from Drosophila models suggested that inhibitors of histone
deacetylases (HDACs) might be used to ameliorate these
transcriptional changes (Steffan et al., 2001). In line with this
hypothesis, it was shown that suberoylanilide hydroxamic
acid (SAHA), a potent HDAC inhibitor, crosses the blood-brain
barrier and increases histone acetylation in R6/2 brains
(Hockly et al., 2003a). Moreover, oral administration of this
compound (starting at postnatal week 5) significantly
improved rotarod performance and reduced the loss of
striatal Nissl staining. However, this treatment had no
ameliorative effect on body weight loss and higher SAHA
doses were shown to be toxic (Hockly et al., 2003a), reflecting
a narrow therapeutic window and indicating that HDAC
inhibitors should be used with caution. Moreover, a closer
scrutiny of the reported positive effects also suggests that
they were mild. For example, SAHA treatment appeared to
induce an analogous improvement in the rotarod perfor-
mance of wild-type mice. Furthermore, the effects on the
morphology of striatal neurons were only descriptive and no
objective quantification was reported.
Sodium butyrate (SB) is another HDAC inhibitor that was
tested in R6/2 mice (Ferrante et al., 2003). Intraperitoneal (i.p.)
administration of this compound extended the survival of R6/
2 mice in a dose-dependent manner (with the highest dose
tested improving the survival of R6/2mice by 20.8%), improved
the rotarod performance and delayed the decrease in body
weight observed in R6/2mice. SB administration reduced brain
weight loss and striatal neuronal atrophy, although no effect
was observed on the number of striatal ubiquitinated neuro-
nal intranuclear inclusions (NIIs) (Ferrante et al., 2003).
Furthermore, treatment with SB increased the acetylation of
histones H3 and H4 and of the transcription factor specific
protein-1 (Sp1) in R6/2 brains. The consequent improvement
of transcriptional regulation (as demonstrated by microarray
analysis) resulted in an increased expression of proteinsinvolved in transcription and metabolism, which, according
to the authors, might contribute for the observed protective
effects of SB (Ferrante et al., 2003).
Since DNA/RNA-binding anthracyclines may have thera-
peutic potential by correcting pathological nucleosome
changes and realigning transcription, Stack et al. (2007b)
have recently tested the effect of the anthracycline chromo-
mycin in R6/2 mice. Chromomycin treatment (starting at
postnatal day 28) realigned chromatin homeostasis, reduced
histone H3 hypermethylation, and restored acetylation of
histone H4 to wild-type levels. Chromomycin treatment also
extended the survival of R6/2 mice by 13.1% and improved
some motor abnormalities. Chromomycin-treated R6/2 mice
also showed a decrease in gross brain atrophy and the average
striatal cell area. Furthermore, chromonycin reduced the brain
levels of 8-hydroxy-2-deoxyguanosine (8-OH2dG), a well-
established marker of oxidative stress, in R6/2 mice. Impor-
tantly, similar results were obtained with a different HD
transgenic mouse model (N171-82Q mice) (Stack et al., 2007b).
In another study, the inhibition of histone H3 methylation
with the antitumor and antibiotic mithramycin (which binds
to guanosine–cytosine-rich DNA sequences and interferes
with several transcription factors of the Sp1 family) also
proved to have beneficial effects in R6/2 mice (Ferrante et al.,
2004). I.p. administration of mithramycin significantly
improved the survival of R6/2 mice in a dose dependent
manner, with the optimal dose extending the survival of R6/2
mice by 29.1%. Moreover, treatment of R6/2 mice with
mithramycin significantly improved rotarod performance
and had a positive effect on brain atrophy, ventricular
enlargement and striatal neuronal atrophy (Ferrante et al.,
2004). The potential beneficial effect of a combined pharma-
cological treatment with mithramycin and cystamine [a
transglutaminase (Tgase) inhibitor; see Section 2.4] in R6/2
mice has also been recently evaluated (Ryu et al., 2006). This
combined therapeutic strategy was shown to reduce hyper-
trimethylation of histone H3 and to extend R6/2 mice survival
over 40%, well beyond any other treatment that has been
reported to date in R6/2 mice. In addition, the combined
treatment significantly improved rotarod performance,
delayed gross brain atrophy, ventricular hypertrophy, striatal
neuronal atrophy, and the number of striatal NIIs (likely due to
cystamine treatment, as mitramycin alone had no effect on
the number of NIIs) (Ryu et al., 2006).
These results suggest that the improvement of gene
transcription, namely by acting at the level of histones, may
have beneficial effects in HD, especially when combined with
other neuroprotective drugs.
2.3. Inhibition of misfolding and oligomerization
Molecular chaperones (including heat shock proteins, HSPs)
prevent the misfolding and consequent aggregation of newly
synthesized stress-denatured proteins and mutant proteins,
thereby reducing the overload of the ubiquitin–proteasome
system that is observed in several neurodegenerative diseases
(for review see Ross and Poirier, 2004). Furthermore, these
proteins co-localize with NIIs in several models of polygluta-
mine diseases (for references see Hansson et al., 2003), and
mutations in HSP70 were shown to increase polyglutamine-
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determine whether overexpression of HSPs could have
beneficial effects in an in vivo HD model, Hansson et al.
(2003) crossed R6/2 mice with mice overexpressing HSP70.
However, overexpression of this molecular chaperone had no
effect on survival, development of paw clasping, and neuro-
pathology (brain weight, striatal atrophy, striatal neuronal
atrophy, and number and size of NIIs) of R6/2 mice. Although
highly expressed in the hippocampus, cortex and striatum,
the cytoplasmic levels of HSP70 seemed reduced in many
neurons, with a clear sequestration into NIIs (Hansson et al.,
2003). In agreement with this study, cross-breeding R6/2 mice
withmice overexpressing a different HSP, HSP27, had no effect
on the development of the R6/2 HD phenotype (Zourlidou et
al., 2007). Therefore, despite their well-established role as
modulators of protein misfolding and consequent aggrega-
tion, overexpression of HSPsmay delay polyglutamine toxicity
only up to a certain level, which may depend on the level of
expression of the mutant protein, the size of the polygluta-
mine tract and the protein context in which it is expressed.
Another study also reported the beneficial effects of Congo
red, an azo-dye that binds preferentially to β-sheets contain-
ing amyloid fibrils and can specifically inhibit oligomerization
(Klunk et al., 1989; Heiser et al., 2000). Congo red administra-
tion, either i.p. or through an intracerebroventricular cannula
(i.c.v.), promoted the clearance of expanded polyglutamine
repeats, reducing the number of aggregates in the basal
ganglia of R6/2 mice. Furthermore, this treatment also
ameliorated the loss of body weight, inhibited the hind limb
dyskinesia (clasping), improved the rotarod performance and
prolonged the life span of these transgenic HD mice by 14.2%.
Since this treatment was started well after the onset of
symptoms (at postnatal week 9), these results strongly
indicate that Congo red not only inhibits polyglutamine
aggregation, but also promotes the disruption of preformed
aggregates, suggesting that aggregation may be crucial for the
toxicity of expanded polyglutamine (Sánchez et al., 2003). This
is a controversial effect that is open for interpretation. It
suggests that the ubiquitin proteasome system is likely to
increase the clearance of soluble ubiquitinylated huntingtin
peptides, ultimately promoting the slow dissociation of large
inclusions and aggregates in the brains of R6/2 mice. In
agreement, NIIs have also been found to disappear in another
mouse model of HD once the transgene was turned off by
administration of doxyciclin, a tetracycline analogue (Tet-Off
regulatory system) (Yamamoto et al., 2000). Nevertheless,
more recently, Wood et al. (2007) failed to replicate the Congo
red data described by Sánchez et al. (2003). Although using a
similar dose and administration regime, Congo red treatment
had no overall effect on survival, motor and cognitive deficits,
as well as on the number of striatal and hippocampal NIIs in
R6/2 mice, and the authors suggest that this lack of effect is
due to the inability of Congo red to cross the blood-brain
barrier (Wood et al., 2007). The reason for this discrepancy is
currently not understood, although differences in the degree
of permeability of the blood brain barrier between the two
mouse coloniesmay account, at least in part, for these results.
However, until this mechanism is fully understood, the
relevance of the results reported initially by Sánchez et al.
(2003) will remain unknown.Tanaka et al. (2004) have shown that various disaccharides
can reduce polyglutamine aggregates and increase survival
in an in vitro model of HD by binding to the expanded
polyglutamine tails and stabilizing the partially unfolded
polyglutamine-containing proteins. Importantly, oral admin-
istration of trehalose (the most effective of these disacchar-
ides) starting at 21 days, was also proven to be beneficial in
R6/2 mice by decreasing the number of polyglutamine
aggregates in their brains, improving their motor dysfunc-
tion (as assessed by the rotarod and the footprint tests), and
extending their lifespan by 10.14% (Tanaka et al., 2004). To
date there has been no demonstration that trehalose crosses
the blood brain barrier and therefore the exact mechanism
of action of this disaccharide deserves further investigation.
Nevertheless, given its lack of toxicity and high solubility,
trehalose might be proven to be a good candidate for future
clinical trials.
The small molecule C2-8 inhibits polyglutamine aggrega-
tion in cell culture and brain slices and rescues neurodegen-
eration in a Drosophila model of HD (Zhang et al., 2005).
Therefore, the same group subsequently assessed its ther-
apeutic potential in R6/2 mice (Chopra et al., 2007). C2-8
(administered orally starting at 3 weeks of age) penetrates the
blood–brain barrier and is present in the brain at a high
concentration. R6/2 mice treated with C2-8 showed improved
motor performance (as assessed by the rotarod and the wire-
hang endurance tests). Furthermore, C2-8 significantly
reduced neuronal atrophy and the size of striatal NIIs.
However, C2-8 treatment had no effect on body weight loss
and survival of these transgenic mice (Chopra et al., 2007).
Nipecotic acid is a Food and Drug Administration (FDA)-
approved compound that significantly reduces mutant hun-
tingtin aggregation and blocks cell toxicity in an inducible cell
model of HD (Wang et al., 2005a,b,c). However, since nipecotic
acid does not cross the blood–brain barrier, the same group
recently evaluated the effects of its analogue, tiagabine (an
FDA-approved anti-convulsive drug, which crosses the blood
brain barrier) in R6/2 mice (Masuda et al., 2008). Six week-old
symptomatic R6/2 mice were treated daily with tiagabine. The
highest dose of tiagabine tested significantly increased the
survival of R6/2 mice by 17.5%, improved motor performance
on the rotarod test at 10 and 12 weeks of age, but had no effect
on the loss of body weight. At the neuropathological level,
tiagabine treatment attenuated brain atrophy but had no
effect on the number of NIIs. Similar beneficial effects were
observed in N171-82Q mice. Importantly, the serum levels of
tiagabine at effective doses in these transgenic models are
comparable to the levels in human patients treated with
tiagabine. Thus, tiagabine may be a promising candidate for
future clinical trials for the treatment of HD (Masuda et al.,
2008).
2.4. Transglutaminase inhibition
Tgase catalyses the formation of γ-glutamyl isopeptide bonds
between polyglutamine tracts and lysine residues. It has been
suggested that this enzyme is involved in NII formation in HD
(Kahlem et al., 1998). However, the number of striatal and
cortical aggregates are increased in a transgenic mouse model
generated by crossbreeding R6/1 mice with “tissue” Tgase
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not be the case (Mastroberardino et al., 2002). Despite an
increase in the number of NIIs, the absence of Tgase did
improve rotarod performance and extend the life span of R6/1
mice by 12% (Mastroberardino et al., 2002). The rather
unexpected finding that an increased level of NIIs is asso-
ciated with a general improvement of R6/1 symptoms and
leads to an increased survival, favors the hypothesis that the
formation of aggregatesmay be a protectivemechanismof the
cell against the more toxic effect of the soluble oligomeric
intermediates of mutant protein, which are believed to be
responsible for many of the intracellular disturbances
observed in HD (for review, Ross and Poirier, 2004).
The use of cystamine (a classical Tgase inhibitor) as a
therapeutic strategy for HD has also been evaluated in R6/2
mice (Dedeoglu et al., 2002; Karpuj et al., 2002). In one study,
i.p. administration of cystamine (starting at 7 weeks of age)
significantly reduced the abnormal movements (resting
tremor, abnormal gait, and grooming), delayed the onset of
clasping and the loss of body weight, and slightly increased
the mean survival of R6/2 mice by 10.7% (Karpuj et al., 2002).
However, no effect on the frequency of NIIs was detected
with this treatment paradigm. In another report, Dedeoglu et
al. (2002) evaluated the effects of cystamine treatment in R6/
2 mice, either by i.p. administration (starting at 21 days of
age), or via the drinking water (starting at the prenatal period
through oral dosing of pregnant females and continuing
post-natal). Cystamine treatment significantly extended the
survival of R6/2 mice (the percentage of increased survival
varied between 16.8% and 19.5%, depending on the dose and
administration paradigm), increased their performance on
the rotarod and improved their body weight, decreased the
loss of brain weight and the gross brain atrophy and reduced
the striatal neuronal atrophy. Furthermore, in this study, a
significant reduction in the number of striatal and cortical
aggregates was detected at 90 days of age (Dedeoglu et al.,
2002). A study by Wang et al. (2005a,b,c) also showed that i.p.
administration of cystamine (starting at 8 weeks) amelio-
rates cerebral glucose metabolism and dopamine (DA) D2
receptor function in the striatum of R6/2 mice, as assessed
by micro positron emission tomography imaging. These
authors also reported a trend towards an increased locomo-
tor activity in the open field test, a non-significant decrease
in the loss of body weight, and a dose-dependent decrease in
the size of striatal NIIs in cystamine-treated R6/2 mice
(Wang et al., 2005a,b,c). Although one can argue that the
discrepancy between these studies regarding the effects of
cystamine (i.e., Tgase inhibition) at the level of NIIs forma-
tion may reflect dosing differences or different starting times
[prenatal/postnatal day 21 (Dedeoglu et al., 2002) versus 7
(Karpuj et al., 2002) or 8 weeks of age (Wang et al., 2005a,b,c)],
one should bear in mind that the complete ablation of the
Tgase gene resulted in an increased number of NIIs in the
R6/1 model (Mastroberardino et al., 2002). Clearly, further
research is needed to clarify the actual contribution of this
enzyme for the formation of NIIs and its role in the
pathology of HD. As suggested by Dedeoglu et al. and further
corroborated by the study of Wang et al., it might be that the
protective effects of cystamine are not directly linked with
Tgase inhibition, but rather with its reported antioxidant andantiapoptotic properties (for references see Dedeoglu et al.,
2002) and/or its ability to increase brain BDNF levels (Borrell-
Pagès et al., 2006).
2.5. Energy supplementation and rescue of metabolic
impairment
Mitochondrial dysfunction, oxidative stress and energy deple-
tion have long been implicated in the pathogenesis of HD (for
review see Gil and Rego, 2008). Therefore, a possible ther-
apeutic approach consists in the administration of com-
pounds that prevent the depletion of ATP or promote
mitochondrial function. Dichloroacetate (DCA), a compound
that stimulates the activity of the pyruvate dehydrogenase
complex (PDHC) (therefore increasing oxidative phosphoryla-
tion), was shown to be therapeutically beneficial in R6/2 mice
(Andreassen et al., 2001c). DCA (dosed orally, through the
drinking water, from 4 weeks of age) significantly improved
rotarod performance, decreased the loss of body weight, and
slightly increased the survival of R6/2 mice by 5.8%. At the
neuropathological level, DCA prevented striatal neuronal
atrophy, but had no effect in the number of striatal and
cortical NIIs. These beneficial effects are thought to be directly
related with the maintenance of normal levels of active PDHC
by DCA, and a resulting decrease in the R6/2 metabolic deficits
(Andreassen et al., 2001c).
A decrease in the activities of mitochondrial complexes II–
III has been implicated in HD (for review see Gil and Rego,
2008). Since the biosynthesis of uridine nucleotides is directly
coupled to the mitochondrial respiratory chain, cells with
impaired mitochondrial function become uridine auxotrophs
and can bemaintainedwith highmicromolar concentration of
uridine and pyruvate. The uridine pro-drug 2′,3′,5′-tri-O-
acetyluridine (PN401) is a pyrimidine nucleoside that was
previously shown to be protective in a 3-nitropropionic acid (3-
NP) lesion model of HD (Saydoff et al., 2003). Recently, these
findings were extended to the R6/2 mouse model (Saydoff et
al., 2006). PN401 was administered orally and the treatment
started between postnatal days 30 and 35. PN401 increased R6/
2 mean survival by 10%, improved rotarod performance,
significantly decreased neurodegeneration in both the cortex
and striatum, and decreased the number of striatal NIIs.
Importantly, this drug was also shown to have similar
beneficial effects in the N171-82Q HD mice model (Saydoff et
al., 2006). In another study, the potential therapeutic effect of
KP544, another substituted pyrimidine that has been shown to
amplify the effects of nerve growth factor (NGF), was also
assessed in R6/2 mice (Dey et al., 2007). Six week-old female
R6/2 mice received KP544 orally and were subsequently tested
(from 8 to 12 weeks of age) on a battery of motor tasks
(clasping assessment, rotarod performance, and spontaneous
activity in the open field). KP544 treatment improved rotarod
performance, reduced the hind limb clasping phenotype, and
delayed the onset of hypoactivity characteristic of R6/2 mice.
At the neuropathological level, KP544 treatment reduced the
enlargement of the lateral ventricles in R6/2 mice (Dey et al.,
2007). However, the effect of KP544 treatment on other
neuropathological hallmarks of the disease (e.g., number of
NIIs) as well as on R6/2 survival was not addressed in this
study.
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various physiological functions through the activation of its
receptors (A1, A2a, A2b, and A3). In early stages of HD (grade 0)
there is a major loss of excitatory A2a receptor [abundant in
striatal γ-aminobutyric acid (GABA)-containing neurons]
binding in the caudate nucleus, putamen and globus pallidus
externus (Glass et al., 2000). Thus, the potential benefits of
CGS21680 (CGS; a selective agonist of adenosine A2a receptors)
were evaluated in the R6/2 HDmousemodel (Chou et al., 2005).
Daily i.p. administration of CGS (starting at 7 weeks) improved
rotarod performance, but had no effect on the life span and
body weight of R6/2 mice. GCS-treated animals showed a
decrease in the enlargement of the lateral ventricles and a
correspondent increase in brain weight and a reduction in the
size of NIIs. Functionally, CGS treatment reversed the elevated
choline/creatine ratio (indicative ofmetabolic impairment and
neurodegeneration) and reduced the activation of 5′AMP-
activated protein kinase (AMPK), amajormetabolic sensor and
downstreammediator of stress-induced pathways, suggesting
that CGS-induced activation of A2a receptors modulates
abnormal metabolic pathways in R6/2 mice. In agreement
with an improved energy metabolism, CGS administration
also decreased the elevated blood glucose levels in diabetic R6/
2 mice (Chou et al., 2005). Further experiments will be needed
to evaluate the effects of an early administration of this
compound on survival, body weight and frequency of NIIs in
the R6/2 mouse model. In a more recent study, an opposite
approach was tested, whereby therapeutic inhibition of the
adenosine A2a receptors was achieved by chronic treatment
with the selective antagonist SCH 58261 (Domenici et al., 2007).
Starting from 5weeks of age, R6/2micewere treated daily with
SCH 58261 for 7 days. This regime fully prevented the
alterations in anxious responses displayed by R6/2 mice
(assessed by the plus-maze test), but had no effect on the
impairment in motor coordination (assessed by the rotarod
test). At the electrophysiological level, SCH 58261 treatment
abolished the increase in N-methyl-D-aspartate (NMDA)-
induced toxicity in R6/2 corticostriatal slices (Domenici et al.,
2007). Because the results obtained by either activating (Chou
et al., 2005) or inhibiting (Domenici et al., 2007) adenosine A2a
receptors at similar symptomatic phases of the disease (5 or
7 week-old) were found to trigger neuroprotective effects in
R6/2 mice, one may deduce that A2a receptors can mediate
different intracellular mechanisms and thus it is not clear
whether therapeutic approaches aimed at targeting this
receptor subtypewill have beneficial outcomes in HD patients.
Creatine kinase and its substrates creatine and phospho-
creatine form an energy-buffering and transport system
between sites of energy production and energy consumption.
As a result, creatine prevents the depletion of the cellular
energy reserves. Moreover, it is believed that creatine can play
a role in themaintenance of intracellular calciumhomeostasis
(for review see Hemmer and Wallimann, 1993). Two studies
have demonstrated that dietary supplementation with crea-
tine has beneficial effects in R6/2 mice, either when the
treatment started at a pre-symptomatic stage (21 days) (Fer-
rante et al., 2000) or at a symptomatic stage (6 and 8 weeks)
(Dedeoglu et al., 2003). In the first study, oral administration of
creatine from 21 days onwards significantly increased the
survival of R6/2 mice by 17.4%. This treatment paradigm alsoimproved rotarod performance throughout the entire life span
of R6/2 mice, increased the gain of body weight, delayed the
loss of brain weight (from 6 to 10 weeks of age) and reduced
gross brain and striatal atrophy, and the number of striatal
NIIs. Interestingly, creatine supplementationalsohadaneffect
on the pancreatic pathology, by decreasing the number of
huntingtin aggregates in the pancreas of 90 days-old R6/2mice
and delaying the onset of diabetes (assessed by a glucose
tolerance test performed at 8.5 weeks of age) (Ferrante et al.,
2000). The survival of R6/2 mice was still improved when the
administration of creatine was initiated at later stages
(Dedeoglu et al., 2003). Thus, initiation of the treatment at
6 weeks of age resulted in an increase in survival by 14.4%,
while at 8 weeks of age the survival increased by 9.7%. Dietary
creatine supplementation started either at 6 or 8 weeks of age
also resulted in an improvement of the rotarod performance.
However, effects on the body weight loss and neuropathology
were only observed inmice treatedwith creatine from 6weeks
of age. In this group, creatine treatment resulted in an increase
in brain weight and striatal area, and a decrease in gross brain
atrophy, striatal neuronal atrophy and number of striatal NIIs
(Dedeoglu et al., 2003). The beneficial effects of creatine seem
to be directly related with an increase in striatal ATP levels
(Dedeoglu et al., 2003), and an overall improvement of the
metabolic state of R6/2mice.Dietary creatine supplementation
was also reported to have similar beneficial effects in another
transgenic mouse model of HD (N171-82Q mice) (Andreassen
et al., 2001a). However, the effects of creatine in these HD
mousemodels could not be reproduced inHDpatients. Indeed,
one year of creatine intake (5 g/day, at a concentration reported
to improvemuscle functional capacity in healthy subjects and
patients with neuromuscular disease) did not improve func-
tional, neuromuscular or cognitive status in stages I and III HD
patients (Verbessem et al., 2003).
2.6. Therapies aimed to ameliorate the diabetic phenotype
As stated above (Section 1), 10–25% of HD patients have been
suggested to display altered glucose metabolism (Podolsky et
al., 1972; Farrer, 1985). However, these estimations were based
on questionnaires and thus no robust clinical evidence
supporting the relationship between HD and diabetes has
been shown to date, making it difficult to interpret the actual
relevance for HD of therapies aimed to treat the diabetic
phenotype. Nevertheless, it is reasonable to speculate that
while these treatments might not be effective in mitigating
the neurological impairment, they might improve certain
peripheral symptoms, and thus the general well-being and
quality of life of patients whomight suffer fromHD-associated
metabolic dysregulation. Interestingly, the diabetic phenotype
is evident in the R6⁄2 mouse model (Hurlbert et al., 1999;
Luesse et al., 2001; Andreassen et al., 2002; Björkqvist et al.,
2005) and may be due to impaired gene expression (Andreas-
sen et al., 2002) and exocytotic defects (Björkqvist et al., 2005).
Thus, this model has also been used to evaluate the efficacy of
various anti-diabetes treatments.
An interesting therapeutic approach based on immuniza-
tion against mutant huntingtin was experimented by Miller et
al. (2003). In this study, 5 and 7 week-old R6/2 mice were
vaccinated with a plasmid encoding a huntingtin N-terminal
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fused to green-fluorescent protein (pHD103-GFP). Interest-
ingly, DNA vaccination prevented the development of the R6/2
diabetic phenotype (as detected by an increased insulin
immunoreactivity in β-cells and normal blood glucose levels
after an overnight fast or a glucose challenge), although these
beneficial effects were not correlated with a decrease in the
number of aggregates in the pancreatic islets. However, DNA
vaccination had no effect on body weight, progression of
motor symptoms and neuropathology of R6/2 mice (Miller et
al., 2003). Although the authors admit that the observed
beneficial effects on the diabetic phenotype may be due, at
least in part, to a nonspecific stimulation of the immune
system (Miller et al., 2003), DNA vaccination may be an option
for the treatment of this peripheral abnormality.
In another study, Hunt and Morton (2005) evaluated the
effect of two oral hypoglycemic agents commonly used in the
treatment of diabetic patients in the development of atypical
diabetes in R6/2 mice. The mice responded acutely to
glibenclamide (which induces exocytosis of insulin) but not
to rosiglitazone (which induces sensitization to insulin),
supporting the idea that in R6/2 mice, the diabetes is caused
by impairment in insulin release rather than insulin insensi-
tivity (Björkqvist et al., 2005). However, chronic treatment with
these hypoglycemic agents (starting at 5.5 weeks of age) had
no effect on survival, weight loss, rotarod performance, and
the course of diabetes (as determined by onset of glycosuria
and blood glucose levels) (Hunt and Morton, 2005). Factors
such as intracellular availability of insulin vesicles ready to be
released, and abnormalities in the exocytotic machinery
(which have been already reported in the R6/2 model) may
contribute to the inefficacy of this chronic treatment.
A recent study has also evaluated the effect ofmetformin, a
widely used anti-diabetes drug, in R6/2 mice (Ma et al., 2007).
The treatment started at 5 weeks of age, and was shown to
prolong the survival of male HD mice by 20.1% and decrease
hind limb clasping in 11-week-old mice. However, metformin
was not effective in female HD mice (Ma et al., 2007), and the
reasons for this gender discrepancy remain unknown.
2.7. Antioxidants
In line with mitochondrial dysfunction and oxidative stress
playing a role in HD (for review see Gil and Rego, 2008),
increasing the antioxidant defenses may also prove to be
beneficial, and several antioxidant compounds have been
tested in R6/1 or R6/2 mice. In one study, the diet of R6/1 mice
was supplemented with several essential fatty acids (linoleic
acid, γ-linolenic acid, eicosapentaenoic acid, docosahexaenoic
acid, α-lipoic acid, d-α-tocopherol acetate) from conception
and throughout adulthood (Clifford et al., 2002). The essential
fatty acids linoleic acid and γ-linolenic acid are crucial for the
regulation of membrane proteins and constitute central
components in several neuronal signaling pathways, whereas
α-lipoic acid (discussed below) and α-tocopherol (vitamin E)
are antioxidant compounds. This dietary supplementation
showed to be effective in ameliorating some of the behavioral
abnormalities (such as clasping, the locomotor impairment,
the reduced rearing and the enhanced grooming) that are
characteristic of the R6 phenotype. Furthermore, this treat-ment seemed to increase the survival of R6/1 mice (within the
43-week period of the study, the mortality appeared to
decrease from 42% in the placebo-treated mice to 15% in the
animals treated with essential fatty acids). However, the
combination of essential fatty acids had no significant effect
on the loss of body weight, and on the decreased expression of
DA D1 and D2 receptors, suggesting that the fatty acids do not
act at the level of the transcriptional abnormalities observed
in these mice (Clifford et al., 2002). Systemic administration of
α-lipoic acid (starting at 4weeks of age) has also been shown to
significantly improve the survival of R6/2 mice, although no
effect on body weight was observed (Andreassen et al., 2001b).
The beneficial effects of this treatment may be related with
the antioxidant properties of lipoic acid, which has been
shown to improve mitochondrial function, decrease oxidative
damage and lipid peroxidation and increase several antiox-
idant defenses, such as α-tocopherol, ascorbate (vitamin C)
and reduced glutathione (Hagen et al., 1999; Arivazhagan et al.,
2001). However, it should be pointed out that the effect of α-
lipoic acid administration was only modest, leading to an
increase in the survival of R6/2mice by 7.1% (Andreassen et al.,
2001b). Therefore, one can speculate that the primary effect of
α-lipoic acid may not necessarily be at the level of the CNS.
It has been shown that the levels of the antioxidant
ascorbate are reduced in the striatal extracellular fluid of R6/
2 mice during periods of behavioral activation (Rebec et al.,
2002). I.p. administration of ascorbate to symptomatic R6/2
mice (from 6 to 10 weeks of age) prevented the decrease of this
vitamin in the striatal extracellular fluid when the animals
became behaviorally active (Rebec et al., 2003). According with
a role of ascorbate in the behavioral phenotype of R6/2 mice,
this treatment significantly reduced stereotypical hind limb
grooming and increased the performance in a plus-maze test,
although no effect was observed on the overall locomotion
(evaluated in an open field apparatus) (Rebec et al., 2003).
Furthermore, restoring the levels of striatal extracellular
ascorbate to wild-type levels was enough to decrease striatal
impulse activity (whichwas shown to be significantly elevated
in these animals), suggesting a role for ascorbate in normal-
izing neuronal function in the striatum of R6/2 mice (Rebec et
al., 2006).
Recently, Smith et al. (2006) have performed a dose ranging
study administering co-enzyme Q10 (an essential cofactor of
the mitochondrial electron transport chain that can act as a
potent antioxidant) in R6/2 mice. The treatment was initiated
at postnatal day 28 and high doses of co-enzyme Q10
significantly extended survival in R6/2 mice up to 25.3%. Co-
enzyme Q10 treatment also resulted in amarked improvement
inmotor performance and grip strength, a reduction in weight
loss, brain atrophy, and NIIs in R6/2 mice. Furthermore, this
treatment elevated co-enzyme Q10 plasma levels and signifi-
cantly increased brain levels of co-enzyme Q9, co-enzyme Q10,
and ATP, while reducing the levels of the oxidative damage
marker 8-OH2dG (Smith et al., 2006).
The administration of tauroursodeoxycholic acid (TUDCA),
a bile acid with antioxidant and antiapoptotic properties,
starting at an early symptomatic stage (6 weeks of age) was
also shown to have beneficial effects in R6/2mice (Keene et al.,
2002). Surprisingly, in contrast to the studies reporting
virtually no striatal cell death until a very late stage of the
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Yu et al., 2003), these authors were able to observe a marked
increase in the number of apoptotic cells [TUNEL (terminal
deoxynucleotidyl transferase-mediated dUTP nick-end label-
ing)-positive cells] in the striatum of R6/2 mice at 13 weeks of
age, a striking finding that was virtually abolished by TUDCA.
Furthermore, TUDCA decreased cerebral atrophy, increased
striatal volume and significantly reduced the number and size
of striatal NIIs. At the behavioral level, TUDCA administration
was shown to increase the activity in the open-field of
10 week-old R6/2 mice as well as the general rotarod
performance of 10–12 week-old animals (Keene et al., 2002).
However, it is difficult to discern the actual robustness of the
effect of TUDCA on this behavioral parameter.
The potential beneficial effect of BN82451, a novel com-
pound with antioxidant and anti-inflammatory properties,
has also been evaluated in R6/2mice (Klivenyi et al., 2003). Oral
administration of BN82451 (starting at 4 weeks of age)
significantly delayed the onset of the HD phenotype and
increased R6/2 mean survival by 15.3%. Although no effect on
the loss of body weight was observed, 10 week-old BN82451-
treated R6/2 mice performed significantly better in the
rotarod, and showed a decrease in gross brain atrophy,
ventricular enlargement, striatal neuronal atrophy and in
the number of striatal NIIs (Klivenyi et al., 2003).
Metals like iron, copper or zinc, which appear to be
increased in brains of HD patients (Dexter et al., 1991), may
participate in the generation of reactive oxygen species and
therefore promote oxidative stress. Therefore, the use of
metal-binding compounds can prove to be an efficient
antioxidant strategy. In line with this idea, Nguyen et al.
(2005) tested the efficiency of the metal-binding compound
clioquinol (5-chloro-7-iodo-8-hydroxy-quinoline) in mitigat-
ing the development of the HD phenotype in R6/2 mice. Orally
administration of clioquinol (starting at 3 weeks of age)
significantly extended the life span of R6/2 mice by 20%,
increased the body weight of 10 and 11 weeks-old mice,
decreased the incidence of clasping and improved rotarod
performance. At the neuropathological level, clioquinol treat-
ment reduced the enlargement of the lateral ventricles (an
indication of striatal atrophy) and significantly decreased the
number of cortical and striatal NIIs. Furthermore, clioquinol-
treated 11 week-old R6/2 mice showed normal fasting blood
glucose and insulin levels comparable to the ones observed in
wild-type controls, indicating that this treatment also ame-
liorated the diabetic phenotype of these mice (Nguyen et al.,
2005).
Supporting the overall results that have been obtained
when treating R6 mice with different antioxidants, recent in
vitro studies have also shown that targeting mitochondrial
defects induced by mutant huntingtin can rescue striatal
neurons (Bae et al., 2005; Benchoua et al., 2006). Therefore,
drugs directed against mitochondrial dysfunction and oxida-
tive stress may also be efficacious in humans.
2.8. Inhibition of excitotoxicity
Excitotoxicity has also been implicated in HD (for review see
Gil and Rego, 2008), and the potential therapeutic effects of
some antagonists of glutamate receptors have been tested inR6 mice. In one of these studies, R6/2 mice were treated either
with remacemide (a low affinity NMDA receptor channel
blocker), co-enzyme Q10 (a lower dose than the one used in the
study by Smith et al., 2006, Section 2.7), or a combination of
both compounds (Ferrante et al., 2002). Oral administration of
remacemide and co-enzyme Q10 alone (starting at the early
age of 21 days) improved the survival of R6/2 mice, by 15.5%
and 14.5%, respectively. However, the combination of both
drugs proved to be evenmore efficient, increasing the survival
of R6/2 mice by 31.8%. Similarly, all three paradigms (rema-
cemide, co-enzyme Q10, and remacemide plus co-enzyme Q10)
significantly improved the performance of R6/2 mice on the
rotarod and decreased the loss of body weight, with the
greatest effect achieved when the two drugs were combined.
Although all three treatments were shown to have beneficial
effects at the neuropathological level (brain weight, gross
brain atrophy, and striatal neuron atrophy), again the
combination of both compounds produced the best results.
Additionally, administration of remacemide plus co-enzyme
Q10 reduced the loss of striatal volume and the number of
striatal NIIs in 9 and 13 week-old R6/2 mice (no results were
presented regarding the effect of each drug alone on these
neuropathological parameters) (Ferrante et al., 2002). Identical
results were observed with another HD transgenic mouse
model (N171-82Q mice) (Ferrante et al., 2002). Interestingly,
even before the publication of these studies, clinical trials
using co-enzyme Q10 (Feigin et al., 1996; Huntington Study
Group, 2001), remacemide and a combination of both com-
pounds (Huntington Study Group, 2001) were conducted in HD
patients with no positive outcome. Indeed, in a multicenter,
parallel group, double-blind, randomized clinical trial per-
formed in HD patients showing early symptoms of HD, the
administration of remacemide, co-enzyme Q10 or a combina-
tion of both over a period of 30 months, produced no
significant effect on the functional decline observed in early
HD (Huntington Study Group, 2001). It might be possible that
the doses given to patients (approximately 5 times less than
the doses used in mice) could not produce sufficient pharma-
cological effects to be protective. Future clinical trials testing
the eficacy of higher doses of these compounds in HD patients
might help clarify this discrepancy.
A different study reported the beneficial effects of riluzole
treatment in R6/2 mice (Schiefer et al., 2002). Riluzole was
shown to reduce the release of glutamate through inactivation
of voltage-dependent sodium channels on glutamatergic
nerve terminals, and through the activation of a G-protein-
dependent signal transduction pathway. Moreover, riluzole
also blocks some of the postsynaptic effects of glutamate by
noncompetitive blockage of NMDA receptors (for review see
Doble, 1996) and is currently used in the clinic for the
treatment of patients with amyotrophic lateral sclerosis (for
review see Bensimon and Doble, 2004). Oral administration of
riluzole (starting at 3 weeks of age) significantly increased the
mean survival of R6/2 mice by 10.2% and delayed the onset of
body weight loss. Analysis of the R6/2 locomotor activity in an
open field apparatus revealed an attenuation of the initial
hyperactive phase in the animals treated with riluzole.
However, no effect on rotarod performance was observed
upon riluzole treatment (Schiefer et al., 2002). Furthermore,
this compound altered the pattern of striatal NIIs, which were
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nated and surrounded by several ubiquitinated nuclearmicro-
aggregates. Based on these observations, these authors
speculate that riluzole might induce an increase in the
degradation of aggregates (Schiefer et al., 2002). However,
one cannot rule out the possibility that riluzole may instead
decrease the initial oligomerization of the mutant protein.
Nevertheless, in a more recent study, oral administration of
riluzole was inefficient at the level of aggregation and did not
improve the R6/2 phenotype (body weight loss, rotarod
performance, grip strength, and open field activity) (Hockly
et al., 2006). Despite these discrepancies, clinical trials of
riluzole in HD patients have been performed (Rosas et al., 1999;
Seppi et al., 2001; Huntington Study Group, 2003; Land-
wehrmeyer et al., 2007). In 2003, the Huntington Study Group
(2003) conducted an 8-week double-blind dose-ranging multi-
center study involving 63 HD patients and found that riluzole
treatment (200 mg/day) ameliorated chorea intensity without
improving functional capacity or other clinical features of
illness. However, in a more recent study involving a total of
379 adult HD patients that were treated with riluzole (50 mg
twice daily) for 3 years, no differences in a combined score
derived from the motor and total functional capacity sub-
scores of the Unified HD Rating Scale were observed between
the patients treated with riluzole and the ones that received
placebo (Landwehrmeyer et al., 2007).
The effects of glutamate release inhibition through stimu-
lation of the presynaptic metabotropic glutamate receptor
(mGluR) 2 or blockage of the postsynaptic excitatory mGluR5
have also been evaluated in R6/2 mice (Schiefer et al., 2004). In
this study, LY379268 (an mGluR2 agonist) or 2-methyl-6-
(phenylethynyl)-pyridine (MPEP; an mGluR5 antagonist) were
orally administered to R6/2 mice starting at the pre-sympto-
matic age of 3.5 weeks. Both compounds were found to
significantly increase R6/2 survival (MPEP by 13.5%; LY379268
by 9.5%), and to attenuate the early hyperactivity (assessed by
the open field test). Additionally, MPEP-treated mice were
shown to perform better on the rotarod, but LY379268 had no
effect on this test of motor coordination. However, none of the
treatments had an effect on the number of NIIs (Schiefer et al.,
2004).
Another factor that can contribute for striatal excitotoxicity
in R6/2 mice is the down-regulation of the primary astroglial
glutamate transporter GLT1, which in turn results in a
deficient glutamate uptake by the glial cells. Thus, Miller et
al. (2008) have recently tested the effects of ceftriaxone, a beta-
lactam antibiotic known to elevate GLT1 expression. Ceftriax-
one was administered to symptomatic 6 week-old R6/2 mice
and the animals were submitted to behavioral testing for
7 days after receiving the last drug injection. Ceftriaxone
attenuated paw clasping and improved motor flexibility (as
measured in a plus maze test, and an open-field apparatus).
As expected, ceftriaxone induced an increase in striatal GLT1
expression and consequently reversed the deficit in glutamate
uptake characteristic of thesemice (assessed bymicrodialysis)
(Miller et al., 2008). Given these promising results, future
studies should investigate whether ceftriaxone treatment (i.e.,
an increase in glutamate uptake by the glial cells) will also
have a long-term effect on the behavior and neuropathology of
R6/2 mice.Since altered afferent neuronal projections may modulate
the release of glutamate, contributing to striatal excitotoxicity
(for review see Gil and Rego, 2008), Stack et al. (2007a)
examined the effects of deafferentation of the corticostriatal
and nigrostriatal pathways in R6/2 mice. Surgical decortica-
tion was performed either at 4 or 6 weeks of age through a
unilateral cortical aspiration lesion targeting the primary
motor cortex, whereas lesion of the nigrostriatal pathway
was performed in 6-week-old R6/2 mice through infusion of 6-
hydroxydopamine into the substantia nigra. Surprisingly, both
cortical and substantia nigra lesions significantly extended
the survival of R6/2 mice (decortication at 4 weeks: by 13.4%;
decortication at 6 weeks: by 8.25%; nigrostriatal deafferenta-
tion at 6 weeks: by 21.29%). Furthermore, both types of lesions
improved the hind limb clasping phenotype. At the neuro-
pathological level, decortication reduced the decrease in
striatal neuronal area and the number of striatal NIIs, but
nigrostriatal deafferentation had no effect on these para-
meters. Importantly, cortical and substantia nigra lesions
resulted in a significant decrease in the striatal levels of either
glutamate or glutamate and DA respectively, a change that
was accompanied by a reduction in the levels of 8-OH2dG and
an increase in the N-acetyl aspartate/creatine ratio, which
might reflect an improvement in neuronal survival (Stack et
al., 2007a).
To summarize, some of the treatments that target excito-
toxicity, as well as mitochondrial dysfunction and oxidative
stress, and that have already been shown to be beneficial in
transgenic mouse models (e.g., riluzole) may ameliorate some
of the symptoms shown by HD patients. Moreover, the
combined use of some of these strategies may produce
cumulative beneficial effects. However, more clinical trials in
HD patients are warranted in order to investigate the actual
value of these combined therapies.
2.9. Caspase inhibition
As discussed above (Section 1), in the R6 model striatal
neuronal death is very limited and most of the studies
reported so far were only able to detect the occurrence of
“dark cell degeneration” in a limited number of striatal
neurons in very late stages of the R6/2 phenotype (Iannicola
et al., 2000; Turmaine et al., 2000; Yu et al., 2003). Nevertheless,
the fact that caspase-1 can cleave both mutant and wild-type
huntingtin in vitro (Wellington et al., 1998) raised the question
whether inhibition of this caspase could interfere with the
progression of the disease. Therefore, Ona et al. (1999)
crossbred R6/2 mice with transgenic mice expressing a
dominant-negative mutant of caspase-1 in the brain (Ona et
al., 1999). Expression of the dominant-negative caspase-1
mutant extended the life span of R6/2 mice by 20% and
significantly delayed the onset of the disease by 7.3 days.
Moreover, this genetic manipulation improved rotarod per-
formance, delayed the loss of bodyweight and the appearance
of NIIs, and significantly inhibited the alterations in the
expression of adenosine A2a, and DA D1 and D2 receptors
(Ona et al., 1999). Furthermore, in the same study the authors
showed that continuous i.c.v. administration of Val-Ala-Asp-
fluoromethyl ketone (zVAD-fmk, a broad caspase inhibitor),
starting at 7 weeks of age, also delayed mortality in the R6/2
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al., 1999). These results supported the idea that caspase-1 was
involved in HD. Besides its role in apoptosis, caspase-1 is also
known to be a mediator of the inflammatory response.
However, the mechanism by which this enzyme contributes
for the neuropathology of R6/2 mice is still not clear, although
caspase-1-mediated cleavage of mutant huntingtin is unlikely
to play a role in this transgenic model (which expresses only
3% of the entire mutant protein).
An alternative strategy that can be applied to decrease
apoptosis is the up-regulation of anti-apoptotic members of
the Bcl-2 family (e.g., Bcl-2 and Bcl-XL). Based on this
assumption, Zhang et al. (2003) crossed R6/2 mice with mice
over-expressing Bcl-2 in neurons. Double transgenic mice
demonstrated a statistically significant delay in the onset of
motor symptoms and an increase in survival by 10.3%.
Behaviorally, over-expression of Bcl-2 only resulted in a non-
significant trend towards a better rotarod performance, and
the effects of this anti-apoptotic protein were not evaluated at
the neuropathological level (Zhang et al., 2003). Although the
results from this study point out for an involvement of the Bcl-
2 family in the R6/2 phenotype (possibly through the regula-
tion of mitochondrial permeability and caspases activation),
no mechanistic results were presented in order to clearly
understand the increased survival observed in the double
transgenic mice.
Tetracyclines are broad-spectrum antibiotics that have
been shown to inhibit caspases and prevent themitochondrial
release of pro-apoptotic factors (Scarabelli et al., 2004) and to
inhibit aggregation in several models of amyloidoses (Forloni
et al., 2001). Although tetracycline itself does not cross the
blood–brain barrier, its derivatives, doxycycline and minocy-
cline, can enter the brain. Based on these properties, several
groups have studied the effects of tetracycline derivatives in
R6/2 mice, reporting contradictory results (Chen et al., 2000;
Smith et al., 2003; Wang et al., 2003). In the first published
study, i.p. administration of minocycline (starting at 6 weeks
of age) significantly extended the survival of R6/2 mice by 14%
and delayed the decline in rotarod performance (Chen et al.,
2000). However, unlike the expression of the dominant-
negative caspase-1 transgene (Ona et al., 1999), minocycline-
mediated inhibition of caspase-1 did not affect NIIs formation
(Chen et al., 2000). Since NIIs can be first detected in the cortex
and striatum as early as 3.5 weeks (Meade et al., 2002), the fact
that minocycline treatment was started at 6 weeks of age
(when NIIs are already widely distributed throughout the
brain), may account for this lack of effect. Minocycline was
efficient in reducing the activities of caspase-1 and the
inducible isoform of nitric oxide synthase (iNOS) and decreas-
ing the up-regulation of caspases 1 and 3 expression in R6/2
brains. On the other hand, the combined i.c.v. administration
of Tyr-Val-Ala-Asp-chloromethyl ketone (YVAD-fmk, a cas-
pase-1-like inhibitor) and Asp-Glu-Val-Asp-fluoromethyl
ketone (DEVD-fmk, a caspase-3-like inhibitor) (starting at
7 weeks of age) significantly improved the rotarod perfor-
mance and extended the survival of R6/2 mice by 17.3% (a
higher increase than the one obtained with minocycline)
(Chen et al., 2000). Thus, the authors speculated that the
observed protective effects of minocycline were related with
caspases inhibition (Chen et al., 2000). A follow-up study alsodemonstrated that i.p. administration of minocycline (from
8.5 to 10.5 weeks of age) significantly inhibited the mitochon-
drial release of the apoptotic proteins AIF (apoptosis inducing
factor), Smac/DIABLO [second mitochondria-derived activator
of caspase/direct IAP (inhibitor of apoptosis protein) binding
protein with low pI], and cytochrome c, and decreased the
activation of caspases 1, 3 and 9 and the cleavage of the pro-
apoptotic factor Bid in brains of symptomatic R6/2mice (Wang
et al., 2003). These results suggested that minocycline acts
upstream of caspases (at the mitochondrial level) and can
interfere with both caspase-independent (AIF) and -depen-
dent (Smac/DIABLO and cytochrome c) mitochondrial cell
death pathways (Wang et al., 2003). However, although
mitochondrial dysfunction (and the consequent metabolic
impairment and oxidative stress) and caspases activation (and
the resulting cleavage of a wide variety of intracellular
proteins, including normal and mutant huntingtin) can
contribute to a generalized cellular dysfunction, one should
take into account that apoptosis is a rare event in R6/2 brains.
Thus, and as mentioned above, the effect that minocycline
may have on caspases-mediated mutant huntingtin cleavage
cannot be properly evaluated in the R6 models. On the other
hand, Smith et al. (2003) failed to reproduce the protective
effects of minocycline on the R6/2 phenotype. In this study,
both tetracycline derivatives doxycycline and minocycline
significantly reduced aggregation in R6/2 hippocampal slice
cultures. However, oral administration of doxycycline or
minocycline (in doses that achieve concentrations in the
brain close to the ones reported to inhibit aggregation in vitro)
had no effect on the loss of body weight, rotarod performance,
grip strength and aggregate load in R6/2 mice. Interestingly,
both tetracycline derivatives reduced the hyperglycemia seen
in late stage R6/2 mice, although this protective effect was not
due to a decrease in the number of aggregates in the islets of
Langerhans (Smith et al., 2003).
A recent study has also evaluated the combined effects of
minocycline and co-enzyme Q10 in R6/2 mice (Stack et al.,
2006). The combined treatment started when the animals
were 26 day-old and was shown to provide enhanced
beneficial effects when compared to both compounds admi-
nistered alone. Thus, while minocycline and co-enzyme Q10
alone extended the survival of R6/2 mice by 11.2% and 14.6%,
respectively, the combination of minocycline and co-enzyme
Q10 extended R6/2 survival by 18.2%. Furthermore, the
combined therapy also improved rotarod performance, atte-
nuated gross brain atrophy, striatal neuron atrophy and
huntingtin aggregation to a greater degree than either
minocycline or co-enzyme Q10 alone (Stack et al., 2006).
Despite the contradictory results that have been reported
in the R6/2 mouse model, clinical trials have been performed
to evaluate the potential beneficial effects of minocycline in
HDpatients (Bonelli et al., 2004; Huntington Study Group, 2004;
Thomas et al., 2004). The first two studies only evaluated the
tolerability of this drug in HD patients and both concluded that
administration of minocycline over a period of 8 weeks
(Huntington Study Group, 2004) and 6 months (Thomas et
al., 2004) was well tolerated and no serious adverse events
were noted. A follow-up two-year study conducted in 11 HD
patients reported an improvement in the general motor and
neuropsychological function of the patients, followed by
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patients also showed a significant amelioration of their
psychiatric symptoms as evaluated by several HD rating
scales (Bonelli et al., 2004). Although these results look
promising and indicate a neuroprotective effect of this agent
in HD (possibly by inhibiting apoptotic neuronal death in the
striatum), a long-term, double-blinded, placebo-controlled
trial should be conducted to definitively establish the value
of minocycline in HD.
2.10. Alternative pharmacological therapeutic strategies
Several other drugs have been tested in the R6 HD transgenic
lines. Lithium has been commonly used as a treatment for
bipolar disorder, showing beneficial effects during both phases
of the disease (mania and depression). Furthermore, lithium
was shown to increase the levels of Bcl-2 and to prolong
survival and the growth and regeneration of axons in the brain
[for references see (Wood and Morton, 2003)]. Based on these
anti-apoptotic and neuroprotective properties and on the fact
that HD patients also suffer from depression, Wood and
Morton (2003 evaluated the effects of chronic administration
of lithium chloride in R6/2 mice. Lithium treatment was
initiated both at pre- and post-symptomatic stages, but no
overall effect on survival was observed in either of the groups.
Surprisingly, lithium treatment seemed to cause distinct
effects in the post-symptomatic group, depending on the
initialweight of the animals. In lightermice, lithium treatment
had adverse effects, whereas in heavier mice treatment with
lithium showed a significant improvement on motor perfor-
mance, although no effects were detected on animal survival
and loss of body weight (Wood and Morton, 2003). These
disparate results are not clearly understood, although the
authors speculate that they may be due to differences in the
ability of individual mice to clear lithium chloride from the
plasma (Wood and Morton, 2003). Nevertheless, the fact that
the deleterious effects were observed in lighter mice suggests
that lithiumchloride can interfere andaggravate themetabolic
abnormalities observed both in R6/2 mice and HD patients.
Inflammation is thought to play a role in the pathogenesis
of HD. Although no major signs of inflammation have been
detected in R6 brains, the up-regulation of certain genes
involved in inflammation (Luthi-Carter et al., 2000) and the
activation of iNOS and caspase-1 (enzymes that are known to
be involved in the inflammatory response) (Chen et al., 2000)
have been reported to occur in R6/2 mice. Within this context,
a recent study evaluated the potential therapeutic benefits of
two commonly used anti-inflammatory drugs (acetylsalicy-
late and rofecoxib, inhibitors of cycloxygenases 1 and 2,
respectively) in both N171-82Q and R6/2 transgenic mouse
models of HD (Norflus et al., 2004). However, the administra-
tion of both drugs fromweaning (at doses comparable to those
tolerated by humans) had no significant effect on survival,
behavioral changes, loss of body weight, or gross cerebral and
striatal atrophy of both N171-82Q and R6/2mice (Norflus et al.,
2004), suggesting that inflammation is not a major contributor
for the pathology of these mice.
Gabapentin (GBP), an anti-convulsant widely used in the
treatment of epilepsy and neuropathic pain syndrome, and its
derivative gabapentin-lactam (GBP-L) have been shown tohave neuroprotective properties that aremediated by the GBP-
L-induced opening of mitochondrial ATP-dependent K+ chan-
nels (for references see Zucker et al., 2004). The efficacy of
these compounds in ameliorating the R6/2 phenotype was
tested through the subcutaneous implantation of GBP- or GBP-
L-delivering pumps into 6 weeks-old R6/2 mice (Zucker et al.,
2004). GBP-L treatment resulted in a non-significant trend
towards an increased survival of about 14%, increased motor
function and coordination, and a reduction in the size and
density of cytoplasmic and nuclear aggregates in the striatum,
neocortex and hippocampus of R6/2 mice. On the contrary,
GBP had no effect on the R6/2 phenotype, further suggesting
that conversion into GBP-L is required for neuroprotection
(Zucker et al., 2004). The precise mechanism behind the
observed beneficial effects of GBP-L was not addressed in
this study. However, as the authors suggest, the GBP-L-
induced opening of mitochondrial ATP-dependent K+ chan-
nels may result in an improvement of neurotransmission,
especially of glutamate release (which is known to be altered
in R6/2 mice). Alternatively, modulation of these channels by
GBP-L may also improve mitochondrial function (which, as
mentioned above, is also disturbed in R6/2 mice). Since the
occurrence of epileptic seizures have been reported to occur in
R6/2 mice, especially during the late stage of the disease
(Mangiarini et al., 1996; Gil et al., unpublished observations),
this therapeutic approach is of particular relevance, and
would be interesting to see if the incidence of epileptic
episodes decrease in animals treated with this anticonvulsant
compound.
Since deregulated gene expression, reduced neurotrans-
mitter levels, and abnormal synaptic function contribute to
the development of the HD-like phenotype in R6/2 mice, a
recent study tested the effects of a combination of drugs
aimed to enhance synaptic function, on the cognitive deficits
of R6/2mice (Morton et al., 2005a). The drugs usedwere tacrine
(an acetylcholinesterase inhibitor that prevents the degrada-
tion of acetylcholine), and moclobemide (an antidepressant
that reversibly inhibits monoamine oxidase A, preventing the
breakdown of noradrenaline and 5-hydroxytryptamine), both
reported to increase the levels of transmitters in the brain [for
references see (Morton et al., 2005a)]. Furthermore, due to its
reported beneficial effects in R6/2 mice (Section 2.5), creatine
was also added to this drug combination (Morton et al., 2005a).
The triple treatment (started at 5 weeks of age) significantly
improved the performance of R6/2 mice on spatial tasks of the
Morris watermaze test, aswell as on a T-maze test. In contrast
to these cognitive improvements, the combined treatment
had only a minor effect on the survival of R6/2 mice and no
significant effects were detected on body weight, rotarod
performance, and number of NIIs. However, the triple treat-
ment had an effect on the progression of the diabetic
phenotype, significantly delaying the onset of glycosuria.
Mechanistically, the observed cognitive improvement is likely
to be related with a significant effect of the triple treatment on
global gene expression patterns. Indeed, many genes signifi-
cantly up- or down-regulated in untreated transgenic animals
returned to normal levels in the triple-treated R6/2 mice
(Morton et al., 2005a).
As stated above (Section 1), there is a disintegration of the
normal sleep–wake cycle (Petersén et al., 2005) and circadian
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deregulation can contribute, at least in part, to the cognitive
deficits observed in these transgenic mice. Thus, in a recent
study R6/2 mice were treated with the sedative drug chloral
hydrate or alprazolam (a short-acting benzodiazepine) to test
whether circadian and cognitive disturbances could be
reversed by imposing a daily cycle of sleep (Pallier et al.,
2007). Daily treatmentwith chloral hydrate (from 9 to 16weeks
of age) or alprazolam (either from 4 to 16 weeks, from 9 to
16 weeks, or from 10 to 17 weeks of age) markedly improved
cognitive performance of R6/2 mice in a two-choice visual
discrimination task. Moreover, alprazolam treatment signifi-
cantly improved the performance of R6/2 mice on the rotarod
test. However, no differences in the overall survival of R6/2
mice were detected following alprazolan treatment, whereas
chloral hydrate had a negative effect on body weight and
survival of these mice (Pallier et al., 2007). Nevertheless, these
results show, for the first time, that treatments aimed at
restoring circadian rhythms may slow the cognitive decline
characteristic of the HD phenotype.
2.11. Transplantation
Transplantation of embryonic stem cells may be an alter-
native therapeutic approach for the treatment of HD. Neural
transplantation studies have been performed in animal
models that showmarked neuronal death (for review, Lindvall
et al., 2004). The R6 mice differ in this respect because they do
not exhibit overt striatal cell loss. Therefore, the aim of neural
grafting in R6 mice would be to replace or improve the
function of dysfunctional neurons. So far, only two studies
have analyzed the effects of neuronal transplantation in R6
mice (Dunnett et al., 1998; van Dellen et al., 2001). One of these
studies evaluated the survival and differentiation of striatal
grafts and their effects on the neurological deficits of R6/2
mice (Dunnett et al., 1998). Striatal tissue was harvested from
embryonic day 14 wild-type mouse embryos and stereotacti-
cally injected into the striatum on both sides of the brain of
10 week-old R6/2 mice. Despite of good survival and apparent
integration within the host brain, the grafts had no effect on
the loss of body weight and the behavioral deficits were only
minimally improved (as assessed by the open field test)
(Dunnett et al., 1998). The lack of positive effects upon
transplantation may be due to a late intervention, and the
same procedure could be repeated in younger pre-sympto-
matic animals in order to clearly evaluate the effects of
striatal grafts on disease progression. In a subsequent study,
van Dellen et al. (2001) transplanted wild-type cortex from
embryos at day 16 into the anterior cingulate cortex of
neonatal R6/1 mice. This procedure had no effect on the
performance of the mice on the horizontal rod test, but was
able to delay the onset of paw clasping, suggesting that this
cortical region (which is one of the sources of the corticos-
triatal fibers that innervate the striatum) is involved in the
development of some of the motor deficit characteristics of
this HD model (van Dellen et al., 2001). The effects of this
repair strategy at the level of survival, loss of body weight and
neuropathology were not evaluated on this study, and there-
fore limited conclusions can be inferred regarding the
beneficial effects of this surgical procedure.A dysfunction of the endosonal/lysosomal pathwaysmight
contribute to protein aggregation and neurodegeneration in
HD (for review see Gil and Rego, 2008). C17.2 neural stem cells
have the potential of differentiating into aneuronal phenotype
and were shown to be effective in the treatment of a variety of
lysosomal storage disorders (for references see Yang and Yu,
2009). Thus, in a very recent study, the efficacy of C17.2 neural
stems cells was tested in R6/2 mice. Mice received a diet
enriched with trehalose (which was previously shown to
decrease aggregate formation; see Section 2.3) starting at
3 weeks of age and at 8 weeks C17.2 cells were transplanted
into their lateral ventricles. This combined treatment
decreased ubiquitin-positive aggregation in the striatum,
reduced the enlargement of the lateral ventricles, delayed the
onset of clasping, improved motor function (assessed by the
footprint test), andextendedR6/2 life spanbyup to 26.3% (Yang
and Yu, 2009), providing a strong basis for the development of
further transplantation protocols for the treatment of HD.
2.12. Genetic manipulations
Gene therapy has been regarded as an attractive alternative
therapeutic strategy for various neurodegenerative diseases.
Moreover, since the primary cause of HD was identified as a
mutation in the huntingtin gene (Huntington's Disease Colla-
borative Research Group, 1993), suppressing the neuronal
expression of mutant huntingtin is expected to delay the onset
and mitigate the severity of the disease. Therefore, a recent
study reported the use of small interfering RNAs (siRNAs)
directed against the huntingtin gene to repress the expression
of the transgenic mutant protein in R6/2 mice (Wang et al.,
2005a,b,c). I.c.v. administration of siRNAs at postnatal day 2
significantly extended the longevity of R6/2mice bymore than
2 weeks (12.4%), slowed down the characteristic loss of body
weight as well as the onset of paw clasping, and improved the
locomotor deficits (assessed by rotarod performance and open
field activity). Furthermore, this approach significantly atte-
nuated the enlargement of the lateral ventricles and
decreased the number of striatal NIIs near the injection site
(Wang et al., 2005a,b,c). Future researchwill be needed in order
to develop safe delivery vectors to target the most affected
neurons in the brain. Importantly, in agreement with this
study DiFiglia et al. (2007) have demonstrated that a single
administration into the adult striatum of an siRNA targeting
mutant huntingtin can silence the mutant gene, attenuate
neuronal pathology, and delay the abnormal behavioral
phenotype observed in a rapid-onset viral transgenic HD
mouse model (DiFiglia et al., 2007).
In addition, Huang and collaborators (2007) generated a
high-capacity adenoviral (HC-Ad) vector expressing a short
hairpin RNA (shRNA) targeted to exon 1 of the huntingtin gene.
Stereotaxic injection of this construct into the striatum of
5 week-old R6/2 mice resulted in a significant reduction in the
number of NIIs (Huang et al., 2007). Since this study only
evaluated the effect of this genetic manipulation on the
number of aggregates, further studies are warranted to test its
effects on survival, behavioral deficits, and other neuropatho-
logical features of the R6/2 mouse model.
Several studies have shown that increased levels of glial
cell line-derived neurotrophic factor (GDNF) can exert
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by intrastriatal injections of excitotoxins (for references see
Popovic et al., 2005), making GDNF a good candidate for gene
therapy in HD. Therefore, in order to evaluate if this
neurotrophic factor was also protective in a chronic mouse
model of HD, Popovic et al. (2005) performed intrastriatal
injections of lentiviral vectors containing the gdnf gene (LV-
GDNF) in 5 week-old R6/2 mice. However, although a
significant increase in the striatal expression of GDNF was
detected in LV-GDNF-injected animals, no behavioral
improvements were observed. Furthermore, at the neuro-
pathological level, no significant differences were seen in the
number of NIIs, striatal neuronal atrophy, and number or
proliferating BrdU-positive cells in the DG of the hippocampus
of these mice (Popovic et al., 2005). The fact that the treatment
was initiated when the animals were 5 week-old (at an age
when NIIs are already formed in the brain), may account for
the lack of effect of GDNF. However, as discussed above,
several other therapeutic strategies have been shown to be
protective, even when started in older animals. Furthermore,
grafting of neural stem cells stably expressing GDNF and the
firefly luciferase gene prevented the degeneration of striatal
neurons and reduced the amphetamine-induced rotational
behavior in an excitotoxic HD mouse model (Pineda et al.,
2007). Nevertheless, the study by Popovic et al. (2005) proves
that overexpression of neurotrophic factors using lentiviral
vectors is doable in the R6 mouse model, and therefore, the
same techniques may be used to evaluate the effects of
overexpression of other neurotrophic factors.
2.13. Therapies aimed to restore neurogenesis
The neuroprotective and neurogenic properties of many
growth factors have been well documented in the literature.
In particular, fibroblast growth factor 2 (FGF2) has been shown
to protect striatal neurons in toxin-induced models of HD,
exert trophic effects on striatal neurons, and stimulate
proliferation of striatal neural stem cells (for references see
Jin et al., 2005). Thus, Jin et al. (2005) evaluated the potential
therapeutic effects of FGF2 in R6/2 mice. FGF2 was adminis-
tered subcutaneously starting at 8 weeks of age. Surprisingly,
FGF2 was shown to stimulate cell proliferation in the
subventricular zone (SVZ) by 150%, as well as the migration
of new neurons from this region into the cerebral cortex and
striatum (where they differentiate into DARPP-32-expressing
medium spiny neurons). Moreover, FGF2 treatment reduced
the number of NIIs, improved rotarod performance, and
increased the average survival of these animals by 20%,
suggesting that potentiation of SVZ neurogenesis may be
used for the treatment of HD (Jin et al., 2005). It remains to be
shown whether FGF2 can also restore DG neurogenesis in
these mice.
Ependymal overexpression of BDNF stimulates neurogen-
esis in the SVZ and integration of new neurons in the
striatum, a process that can be potentiated by noggin-induced
suppression of subependymal gliogenesis and increase in
progenitor availability (for references see Cho et al., 2007).
Thus, in a recent study 4- and 6-week-old R6/2 mice received
intraventricular injections of adenoviral BDNF (AdBDNF) and
adenoviral noggin (AdNoggin), which suppress astroglialdifferentiation by subependymal zone progenitor cells,
thereby promoting their neuronal differentiation. Recruit-
ment of βIII-tubulin-positive and doublecortin-positive neu-
rons, which developed as DARPP-32-positive and became
GABAergic medium spiny neurons that expressed either
enkephalin or substance P and extended fibers to the globus
pallidus, was observed in AdBDNF/AdNoggin-treated R6/2
mice. Importantly, AdBDNF/AdNoggin treatment also
improved rotarod performance and open-field activity and
increased the survival of R6/2 mice by 16.8% (Cho et al., 2007).
Given these promising results, it would be interesting to
evaluate the effects of AdBDNF/AdNoggin treatment on the
striatal neuropathology of R6/2 mice. Indeed, the importance
of BDNF in HD neurodegeneration was previously demon-
strated by disrupting the expression of the bdnf gene in R6/1
mice (Canals et al., 2004). Decreased levels of this neurotro-
phin were shown to advance the onset of motor dysfunction
and cause the specific degeneration of enkephalinergic
striatal projection neurons (the most affected neurons in
HD). Importantly, this neuronal dysfunction was restored by
administration of exogenous BDNF, suggesting that this
neurotrophic factor might help delaying or stopping illness
progression (Canals et al., 2004). More recently, CEP-1347, a
mixed lineage kinase inhibitor with neuroprotective and
neurotrophic effects, was shown to restore the expression of
BDNF (Apostol et al., 2008; Conforti et al., 2008) and improve
motor performance in R6/2 mice (Apostol et al., 2008).
Erythropoietin (EPO) is a cytokine that is produced in the
kidneys and regulates haematopoiesis. EPO has been found to
enter the brain after peripheral administration, where it can
act through the activation of brain EPO receptors and several
studies showed robust neuroprotective effects in various
models of acute neurodegeneration (for references see Gil et
al., 2004). The natural EPO metabolite asialoerythropoietin
(asialoEPO) has the same neuroprotective potency as EPO, can
equally cross the intact blood-brain barrier, and has the
advantage of not affecting the hematocrit (Erbayraktar et al.,
2003). Based on these properties and on the reported neuro-
genic effect of this cytokine,we evaluated the effects of chronic
administration of asialoEPO in the locomotor deficits, neuro-
pathology and reduced hippocampal cell proliferation in R6/2
mice (Gil et al., 2004). However, asialoEPO treatment (starting at
5 weeks of age) had no effects on rotarod performance, paw
clasping, open field activity, and any of the neuropathological
parameters evaluated (number of striatal NIIs, striatal atrophy
and striatal neuronal atrophy). Furthermore, asialoEPO admin-
istration did not prevent the significant decrease in hippo-
campal cell proliferation observed in the DG of 12week-old R6/
2mice (Gil et al., 2004). The lackof effects of asialoEPO in theR6/
2 mice indicates that this drug is not as neuroprotective in
chronic neurodegenerative models (with limited cell death) as
in acute situations. Furthermore, one of the proposed EPO
neuroprotective mechanisms involves the nuclear factor-κB
(NF-κB)-mediated up-regulation of neuroprotective and anti-
apoptotic genes (for references see Gil et al., 2004). Thus,
transcriptional abnormalities, which are believed to play an
important role in the pathology of R6/2mice,may account for a
lack of asialoEPO neuroprotection in this model.
Since physical activity is known to stimulate adult
hippocampal neurogenesis, Kohl et al. (2007) examined
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campal neurogenesis in 5 week-old R6/2 mice, by housing
them with free access to running wheels. However, a 4-week
running period failed to stimulate proliferation and survival of
newly generated neurons in the R6/2 mice. Although the
authors suggest that the mechanisms responsible for up-
regulating neurogenesis following physical exercise might be
compromised in R6/2 mice, a different explanation for these
findings might be that the R6/2 mice simply just did not
exercise enough due to their locomotor impairments.
Antidepressants that act as serotonin reuptake inhibitors
are also known to stimulate neurogenesis. Thus, Grote et al.
(2005) sought to investigate the effects of the antidepressant
fluoxetine in R6/1 mice. Fluoxetine treatment (starting at
4 weeks of age) improved hippocampal-dependent cognitive
function (assessed by a T-maze test) and reversed the
depressive phenotype (evaluated with the Porsolt forced
swim test), but had no effect on the locomotor deficits and
the loss of bodyweight characteristic of these transgenicmice.
Importantly, fluoxetine also rescued the neurogenic process in
the R6/1 DG, strongly supporting the hypothesis that modula-
tion of hippocampal neurogenesis might improve cognitive
function in HD (Grote et al., 2005). In a more recent study, Peng
et al. (2008) tested the potential benefitial effects of another
serotonine reuptake inhibitor sertraline in R6/2 mice. Sertra-
line treatment was initiated when the mice were 6 weeks of
age and was shown to prolong R6/2 survival in a dose-
dependent manner (5 mg/kg by 13%; 10 mg/kg by 20%) but had
no effect on the loss of body weight. Furthermore, sertraline-
treated R6/2 mice performed significantly better on the
rotarod test at 10 weeks of age. At the neuropathological
level, sertraline treatment ameliorated striatal atrophy and
the enlargement of the lateral ventricles, but had no effect on
the number of NIIs. Interestingly, these beneficial effects are
associated with an increase in brain BDNF levels and
neurogenesis (cell proliferation and survival of the newly
generated cells) in the DG of R6/2 mice (Peng et al., 2008).
Similar results have also been obtained with a different HD
transgenic model (the N171-82Q mouse model) (Duan et al.,
2008). Importantly, the serum and brain levels of sertraline
that were shown to be beneficial in these transgenic models
are comparable to the levels achieved in humans treated with
this antidepressant, making sertraline an interesting candi-
date for HD clinical trials. Nevertheless, one should keep in
mind that the behavioral improvement observed upon treat-
ment with trophic factors (e.g., BDNF) and serotoninergic
agents might not be a direct consequence of increased cell
proliferation. Furthermore, the actual implications of reduced
hippocampal cell proliferation for the development of cogni-
tive deficits in HD remais to be elucidated.3. Concluding remarks
There are today over 100 publications reporting the effects of a
variety of therapeutic strategies in the pathology of R6
transgenic HD mice. The findings from all these studies
suggest that the phenotype of these transgenic models may
be due to several parallel pathological events, both within the
nervous system and in peripheral tissues. Thus, to success-fully treat these mice, and most likely human HD patients as
well, it might be necessary to apply several different ther-
apeutic strategies simultaneously. Although several of the
studied therapies were proven to exert certain beneficial
effects individually, the search continues for a combination of
treatments that may also be of significant clinical relevance.
Naturally, as discussed above, there is concern that the R6
micemay not model critical aspects of the pathogenic process
inHD and therefore therapies that are effective in R6micemay
not turn out to be relevant in patients (as in the case of
creatine, co-enzyme Q10, and remacemide). Nevertheless, the
characterization of the R6 transgenic HD mouse has greatly
increased our understanding of the pathogenic process in HD.
Thus, by paralleling findings in mice and humans, important
similarities and discrepancies will continue to be identified,
which will further increase the understanding of the disease
and ultimately the identification of more effective therapies.Acknowledgments
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